Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes

Xenobiotica

Volumn 33, Issue 3, 2003, Pages 265-276

  Bachmann, K ^a   He, Y ^a   Sarver, J G ^a   Peng, Ning ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 HYDROXYETHYL) 2 METHYLSUCCINIMIDE; 2 (2 HYDROXYETHYL) 2 METHYLSUCCINIMIDE; 2 CARBOXYMETHYL 2 METHYLSUCCINIMIDE; 2 ETHYL 3 HYDROXY 2 METHYLSUCCINIMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; ENZYME ANTIBODY; ETHOSUXIMIDE; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; LIVER MICROSOME; PROTEIN EXPRESSION;

ALGORITHMS; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ETHOSUXIMIDE; HUMANS; HYDROXYLATION; ISOENZYMES; KINETICS; MICROSOMES, LIVER; NADP;

EID: 0037357282     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825021000061606     Document Type: Article

References (30)

1. BACHMANN, K. A., CHU, C. A. and GREEAR, V., 1992, In vivo evidence that ethosuximide is a substrate for cytochrome P450 IIIA. Pharmacology, 45, 121-128.
2. BACHMANN, K. A. and JAUREGUI, L., 1993, Use of single clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica, 23, 307-315.
3. DIEM, K. AND LENTNER, C. (eds), 1970, Documenta Geigy. Scientific Tables, 7th edn (Basle: Ciba-Geigy).
4. GENTEST CORPORATION, 1997, 1996-1997 Catalog (Woburn: Gentest Corp.).
5. GIACCONE, M., BARTOLI, A., GATTI, G., MARCHISELLI, R., PISANI, F., LATELLA, M. and PERUCCA, E., 1996, Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. British Journal of Clinical Pharmacology, 41, 575-579.
6. HORNING, M. G., STRATTON, C., NOWLIN, J., HARVEY, D. J. and HILL, R. M., 1973, Metabolism of 2-ethyl-2-methylsuccinimide (ethosuximide) in the rat and human. Drug Metabolism and Disposition, 3, 569-576.
7. HUNT, C., WATKINS, P., SAENGER, P., STAVE, G., BARLASCINI, N., WATLINGTON, C., WRIGHT, J., JR and GUZELIAN, P., 1992, Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18-23.
8. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147-171.
9. KINIRONS, M., OSHEA, D., DOWNING, T., FITZWILLIAM, A., JOLLENBECK, L., GROOPMAN, J., WILKINSON, G. and WOOD, A., 1993, Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621-629.
10. KINIRONS, M., OSHEA, D., KIM, R., GROOPMAN, J., THUMMEL, K., WOOD, A. J. and WILKINSON, G. R., 1999, Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P453A. Clinical Pharmacology and Therapeutics, 66, 224-231.
11. KRIVORUK, Y., KINIRONS, M., WOOD, A. and WOOD, M., 1994, Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clinical Pharmacology and Therapeutics, 56, 608-614.
12. LEWIS, D. F. V., 2000, On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Towards the prediction of human P450 substrate specificity and metabolism. Biochemical Pharmacology, 60, 293-306.
13. MAURER, H. H., 1990, Detection of anticonvulsants and their metabolites in urine within a general unknown analysis procedure using computerized gas chromatography-mass spectroscopy. Archives of Toxicology, 64, 554-561.
14. MILLERSHIP, J. S., COLLIER, P. S., HAMILTON, J. T. G., MCROBERTS, W. C. and MISFUD, J., 1995, Chiral aspects of the metabolism of ethosuximide. Chirality, 7, 173-180.
15. MILLERSHIP, J. S., MISFUD, J. and COLLIER, P. S., 1993, The metabolism of ethosuximide. European Journal of Drug Metabolism and Pharmacokinetics, 18, 349-353.
16. PAINE, M., SHEN, D., KUNZE, K., PERKINS, J., MARSH, C., MCVICAR, J., BARR, D., GILLIES, B. and THUMMEL, K., 1996, First-pass metabolism of midazolam by the human intestine. Clinical Pharmacology and Therapeutics, 60, 14-24.
17. PETTERSEN, J. E., 1980, Studies on the metabolism of the antiepileptic drug 2-ethyl-2-methylsuccinimide by combined GCMS. Advances in Mass Spectroscopy, 8B, 1291-1297.
18. PISANI, F. and BIALER, M., 1995, Ethosuximide chemistry and biotransformation. In R. H. Levy, R. H. Mattson and B. S. Meldrum (eds), Antiepileptic Drugs (New York: Raven), pp. 655-665.
19. SARVER, J. G., BACHMANN, K. A., ZHU, D. and KLIS, W. A., 1998, Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes. Drug Metabolism and Disposition, 26, 78-82.
20. SHIMADA, T., TSUMURA, F. and YAMAZAKI, H., 1999, Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metabolism and Disposition, 27, 1274-1280.
21. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
22. SLAMA, J., HANCOCK, J., RHO, T., SAMBUCETTI, L. and BACHMANN, K. 1998, Influence of some novel N-substituted azoles and pyridines on rat hepatic CYP3A activity. Biochemical Pharmacology, 55, 1881-1892.
23. STEIN, C. M., KINIRONS, M., PINCUS, T., WILKINSON, G. and WOOD, A., 1996, Comparison of the dapsone recovery ratio and erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clinical Pharmacology and Therapeutics, 59, 47-51.
24. THUMMEL, K., OSHEA, D., PAINE, M., SHEN, D., KUNZE, K., PERKINS, J. and WILKINSON, G., 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics, 59, 491-502.
25. THUMMEL, K. E. and SUEN, D., 2001, Design and optimization of dosage regimens: pharmacokinetic data. In J. Hardman, L. Limbird and A. Goodman Gilman (eds), The Pharmacological Basis of Therapeutics, 10th edition (New York: McGraw-Hill), pp. 1917-2023.
26. THUMMEL, K., SHEN, D., PODOLL, T., KUNZE, K., TRAGER, W., BACCHI, C., MARSH, C., MCVICAR, J., BARR, D., PERKINS, J. and CARITHERS, R., 1994b, Use of midazolam as a human cytochrome P4503A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271, 557-566.
27. THUMMEL, K. E., SHEN, D., PODOLL, T., KUNZE, K., TRAGER, W., HARTWELL, P., RAISYS, V., MARCH, C., MCVICAR, J., BARR, D., PERKINS, J. and CARITHERS, R., 1994a, Use of midazolam as a human CYP3A probe: I. in vitro-in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549-556.
28. VENKATAKRISHNAN, K., VON MOLTKE, L., COURT, M., HARMATZ, J., CRESPI, C. and GREENBLATT, D., 2000, Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition, 28, 1493-1504.
29. WATKINS, P., 1994, Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171-184.
30. WATKINS, P., TURGEON, D., SAENGER, P., LOWN, K., KOLARS, J., HAMILTON, T., FISHMAN, K., GUZELIAN, P. and VOORHEES, J., 1992, Comparison of urinary 6-β-cortisol and erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clinical Pharmacology and Therapeutics, 52, 265-273.